TSBX Turnstone Biologics Corporation: Enterprise Value-to-Revenue Multiple

Public company logo of Turnstone Biologics Corp (TSBX)

The reliability of Turnstone Biologics (TSBX) therapy relies on strict adherence to temperature controls during the transportation of viral drugs. The EV/Sales history demonstrates the valuation dynamics of the business excluding debt, where the value of characterizes this level. Diversification of clinical trial targets reduces regulatory risks, while high demand for solid tumor treatment facilitates the expansion of the partner medical center network.

Company Value to Revenue: Turnstone Biologics Corporation (TSBX) for 07/04/2022 - 11/20/2026

Turnstone Biologics Corporation - analytical breakdowns and key metrics (TSBX)

- share price and consensus valuation forecast:
Initial company analysis:Turnstone Biologics Corp TSBX
Product sample of Turnstone Biologics Corp

The stability of this metric confirms the long-term reliability of the issuer, reflecting the market value of the business minus net debt per unit of revenue. By analyzing the enterprise value-to-annual revenue multiple, the investor assesses the capitalization efficiency of Turnstone Biologics (TSBX) within the context of its expansion into the TIL therapy sector for treating solid tumors and its capture of the immuno-oncology niche.

Competitor analysis for Turnstone Biologics

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|werewolftx.com (HOWL) - Enterprise Value-to-Revenue Multiple|Immix Biopharma Inc. - EV/Sales Multiple|ALXO - EV/Sales Multiple|CUE: EV/Sales Multiple|Company Value to Revenue Ratio PDSB|Enterprise Value-to-Revenue Ratio Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple LIMN|EV/Sales Multiple Lava Tx (LVTX)|EV/Sales Multiple NXTC (NextCure Corporation)|Business Value to Revenue LPTX|INTS - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Sensei Biotherapeutics Inc SNSE|TOVX: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Gritstone Bio (GRTS)|KA (Kineta Corp) - EV/Sales Multiple|Company Value to Revenue Ratio NEXI (NexImmune Corp)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP